Capromab
Capromab is an anti-human PSMA-targeting monoclonal antibody. Capromab binds specifically to the intracellular domain of PSMA, does not undergo internalization after binding, and targets necrotic cells with disrupted membranes. Capromab can be used for the research of prostate cancer.
Nos produits utilisent uniquement pour la recherche. Nous ne vendons pas aux patients.
- CAS No.: 151763-64-3
-
Stockage:
Please store the product under the recommended conditions in the Certificate of Analysis.
Activité biologique
Mouse IgG1 kappa
Human
Capromab (Radiolabeled) (10 nM; 2 h) binds specifically to permeabilized PSMA-expressing LNCaP cells, with minimal unspecific binding to PSMA-negative PC3 cell membranes[1].
Capromab (125I-capromab) (10 nM) retains an immunoreactive fraction of 83 ± 2% when binding to PSMA-expressing LNCaP cell membranes[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:BALB/c nu/nu mice (male; subcutaneous PC3 xenograft, 3 weeks post-injection)[1]
-
Dosage:3 μg total antibody per animal
-
Administration:i.v. (tail vein); single dose
-
Result:Showed significantly lower (p < 0.01) tumor uptake in PSMA-negative PC3 xenografts compared to PSMA-positive LNCaP xenografts, with uptake levels comparable to muscle tissue.
FOLH1/PSMA
Unconjugated
The product can be reconstituted/diluted with sterile PBS or saline.
-
Product Image
ELISA, FACS, Functional assay
Chemical Information
-
CAS No. 151763-64-3
-
SMILES
[Capromab]
-
Formulation
Please refer to the lot-specific COA for specific buffer information.
-
Stockage
Please store the product under the recommended conditions in the Certificate of Analysis.
Pureté et documentation
Références
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)